Technology areas: Biotechnology & Pharmaceuticals • Communications
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Xilis Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners and are distributed across 2 distinct art units. This distribution means that each pending matter is being reviewed by a different examiner in a different technical group. This one-to-one relationship between actions, examiners, and units suggests a highly individualized prosecution path for each application.
The busiest examiner, MARVICH, MARIA, is responsible for 1 pending office action. This accounts for half of the 2 pending office actions currently active for the company. Because there are 2 distinct examiners and 2 distinct art units, each application is being reviewed by a unique examiner in a unique technical group. This lack of overlap means that the outcomes of the 2 pending office actions are likely to be independent of one another.
Practitioners managing this portfolio in the Biotechnology & Pharmaceuticals area must tailor their strategies to the specific requirements of 2 distinct art units. With 2 distinct examiners involved, there is no opportunity to leverage a single relationship to advance multiple cases. The 2 pending office actions represent the entirety of the company's current active matters, requiring a focused effort on two separate fronts within the USPTO. This structure emphasizes the need for distinct technical arguments for each filing.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
| TORRES, JOSE | 1 | 82.0% | +12.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18827077 | IMAGING-BASED DROPLET DRUG ASSAYS | TORRES, JOSE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861120 | METHODS AND APPARATUSES FOR TESTING HEPATOCYTE TOXICITY USING MICROORGANOSPHERES | MARVICH, MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861120 | METHODS AND APPARATUSES FOR TESTING HEPATOCYTE TOXICITY USING MICROORGANOSPHERES | MARVICH, MARIA | — |
| 18827077 | IMAGING-BASED DROPLET DRUG ASSAYS | TORRES, JOSE | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 2664 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18861120 | METHODS AND APPARATUSES FOR TESTING HEPATOCYTE TOXICITY USING MICROORGANOSPHERES | MARVICH, MARIA | 1634 | §101§102§112 | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18827077 | IMAGING-BASED DROPLET DRUG ASSAYS | TORRES, JOSE | 2664 | DP | Non-Final OA | — | Pending | Sep 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXilis Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Maria Marvich has the most, with 1 of Xilis Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
